Strategy Escalation: An emerging paradigm for safe clinical development of T cell gene therapies

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Junghans, Richard P ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN PRESENTING CELL; CELL BASED GENE THERAPY; CELL PROLIFERATION; CYTOTOXICITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTOXICITY; NOTE; REGULATORY T LYMPHOCYTE; RISK FACTOR; T LYMPHOCYTE; TUMOR REGRESSION; ARTICLE; GENE THERAPY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; SAFETY;

GENE THERAPY; HUMANS; IMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL; SAFETY; T-LYMPHOCYTES;

EID: 77954854070     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-55     Document Type: Note

References (41)

1. Ma QZ, Gonzalo-Daganzo R, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. Cancer Chemotherapy & Biological Response Modifiers - Annual 20 2002, 319-45. Oxford: Elsevier Science, Giaccone R, Schlinsky R, Sondel P.
2. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006, 24:e20-2. 10.1200/JCO.2006.05.9964, 16648493.
3. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, White DE, Steinberg SM. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988, 319:1676-80.
4. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006, 12(20 Pt 1):6106-15. 10.1158/1078-0432.CCR-06-1183, 2154351, 17062687.
5. Warren RS, Fisher GA, Bergaland EK, Pennathur-Das R, Nemunaitis J, Venook AP, Hege KM. Studies of regional and systemic gene therapy with autologous CC49-zeta modified T cells in colorectal cancer metastatic to liver. (Abstract, 7th International Conference on Gene Therapy of Cancer). Cancer Gene Ther 1998, 5:S1-S2.
6. Junghans RP, Safar M, Huberman MS, Ma Q, Ripley R, Leung S, Beecham EJ. Preclinical and phase I data of anti-CEA "designer T cell" therapy for cancer: A new immunotherapeutic modality. Proc Am Soc Clin Oncol 2001, A1063.
7. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC. Adoptive transfer of chimeric antigen receptor redirected cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-33.
8. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-70. 10.1038/nm.1882, 2749734, 18978797.
9. Scheinberg DA, Mulford DA, Jurcic JG, Sgouros G, Junghans RP. Antibody therapies of cancer. Cancer Chemotherapy and Biotherapy: Principles and Practice 2006, 666-98. Lippincott, Wheeler and Wilkins, Philadelphia, Chabner BA, Longo DL.
10. Stone JD, Stern LJ. CD8 T cells, like CD4 T cells, are triggered by multivalent engagement of TCRs by MHC-peptide ligands but not by monovalent engagement. J Immunol 2006, 176:1498-505.
11. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23:2346-57. 10.1200/JCO.2005.00.240, 1475951, 15800326.
12. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-9. 10.1200/JCO.2008.16.5449, 2652090,2652090, 18809613.
13. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008, 181:329-42. full_text, 18071952.
14. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006, 20:1819-28. 10.1038/sj.leu.2404366, 16932339.
15. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-8.
16. Sykes M, Spitzer TR. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies. Cancer Treat Res 2002, 110:79-99.
17. Junghans RP, Abedi M, Ma Q, Davies R, Bais A, Gomes E, Beaudoin E, Lu L, Davol P, Cohen SI. Phase I trial of anti-PSMA designer T cells in advanced prostate cancer. Proc Am Assoc Cancer Res 2009, A5662. Denver CO.
18. Perez A. Cardiac toxicity of ErbB2-targeted therapies: what do we know?. Clin Breast Cancer 2008, 8(suppl 3):S114-20. 10.3816/CBC.2008.s.007, 18777950.
19. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New Eng J Med 2000, 343:750-8. 10.1056/NEJM200009143431101, 10984562.
20. Junghans RP. Phase I study of T cells modified with chimeric anti-CEA immunoglobulin-T cell receptors (IgTCR) in adenocarcinoma. , http://clinicaltrials.gov/show/NCT00004178
21. Junghans RP. Phase I trial of 2nd generation anti-CEA designer T cells in gastric cancer. , http://clinicaltrials.gov/show/NCT00429078
22. Junghans RP. Phase Ia/Ib trial of anti-PSMA designer T cells in advanced prostate cancer after non-myeloablative conditioning. , http://clinicaltrials.gov/show/NCT00664196
23. Crystal RG. Translating stem cell therapy to the clinic: déjà vu all over again. Mol Ther 2009, 17:1659-60. 10.1038/mt.2009.215, 19789557.
24. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010, 18:666-8. 10.1038/mt.2010.31, 20357779.
25. Brentjens R, Riviere I. Phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19. , http://clinicaltrials.gov/ct2/show/NCT00466531
26. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-51. 10.1038/mt.2010.24, 20179677.
27. Rosenberg SA. Phase I/II study of metastatic cancer that expresses Her-2 using lymphodepleting conditioning followed by infusion of anti-Her-2 gene engineered lymphocytes. , http://clinicaltrials.gov/ct2/show/NCT00924287
28. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990, 5:953-62.
29. Hekman A, Honselaar A, Vuist WM, Sein JJ, Rodenhuis S, Huinink ten Bokkel WW, Somers R, Rümke P, Melief CJ. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 1991, 32:364-72. 10.1007/BF01741331, 1706642.
30. Finn RS, Slamon DJ. Monoclonal antibody therapy for breast cancer: Herceptin. Cancer Chemother Biol Response Modif 2003, 21:223-33.
31. Ma QZ, DeMarte L, Wang YW, Stanners CP, Junghans RP. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA chimeric immune receptor modified T cells: representative of a new class of Ig fusion proteins. Cancer Gene Therapy 2004, 11:297-306. 10.1038/sj.cgt.7700685, 15002034.
32. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999, 59(7 Suppl):1693s-1700s.
33. Heslop HE. Safer CARS. Mol Ther 2010, 18:661-2. 10.1038/mt.2010.42, 20357776.
34. Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther 2010, 21:241-50. 10.1089/hum.2010.014, 20121594.
35. Sprengel R, Hasan MT. Tetracycline-controlled genetic switches. Handb Exp Pharmacol 2007, 178:49-72. full_text, 17203651.
36. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-46. 10.1182/blood-2009-03-211714, 19451549.
37. Parkhurst MR, Yang JC, Langan RC, Feldman SA, Dudley ME, Robbins PF, Rosenberg SA. Adoptive transfer of peripheral blood lymphocytes genetically modified to express a T cell receptor recognizing carcinoembryonic antigen into patients with metastatic colorectal cancer induced inflammatory colitis without mediating anti-tumor effects. American Society of Gene and Cell Therapy 2010 annual meeting. Molecular Ther 2010, 18(suppl 1):A25.
38. Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RL. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 2000, 7:1369-77. 10.1038/sj.gt.3301253, 10981663.
39. Yang W, Beaudoin E, Lu L, Du Pasquier RA, Kuroda MJ, Willemsen R, Koralnik IJ, Junghans RP. Chimeric immune receptors specific to JC virus for immunotherapy of progressive multifocal leukoencephalopathy. Int Immunol 2007, 19:1083-93. 10.1093/intimm/dxm076, 17660502.
40. Boyman O, Létourneau S, Krieg C, Sprent J. Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol 2009, 39:2088-94. 10.1002/eji.200939444, 19637200.
41. Min B, Foucras G. Meier-Schellersheim M, Paul WE. Spontaneous proliferation, a response of naive CD4 T cells determined by the diversity of the memory cell repertoire. Proc Natl Acad Sci USA 2004, 101:3874-9. 10.1073/pnas.0400606101, 374337, 15001705.